A similar phase 2 study conducted by the Groupe Francophone Des Myelodysplasies (GFM) in a high-risk elderly population of TP53 mutated MDS and AML patients reported response rate of 76%, including 53% CR/CRi [65]. The gene discussed is TP53; the disease is myelodysplastic syndrome.